David Risinger
Stock Analyst at Leerink Partners
(3.72)
# 797
Out of 4,711 analysts
166
Total ratings
65.52%
Success rate
17.72%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Upgrades: Outperform | $206 | $175.58 | +17.33% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $57.33 | +27.33% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $47.44 | +45.45% | 2 | Nov 11, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $5.61 | +185.20% | 1 | Oct 24, 2024 | |
| REGN Regeneron Pharmaceuticals | Downgrades: Market Perform | $1,175 → $1,077 | $701.85 | +53.45% | 7 | Sep 24, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $44 | $20.31 | +116.64% | 2 | Sep 17, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $106 → $153 | $86.53 | +76.82% | 2 | Sep 3, 2024 | |
| TBPH Theravance Biopharma | Downgrades: Market Perform | $15 → $10 | $9.59 | +4.28% | 3 | Aug 6, 2024 | |
| HLVX HilleVax | Downgrades: Market Perform | $28 → $2 | $1.86 | +7.53% | 2 | Jul 9, 2024 | |
| ANAB AnaptysBio | Initiates: Outperform | $47 | $14.55 | +223.02% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $263.38 | +20.74% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $17.16 | -35.90% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $767.76 | -40.35% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $42 | $46.96 | -10.56% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $374 → $365 | $397.27 | -8.12% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $92.57 | -1.70% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $26.36 | +82.09% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $194 → $186 | $144.47 | +28.75% | 2 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $11.57 | -13.57% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $10 | $15.52 | -35.57% | 2 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $14.58 | +153.77% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $122.97 | +43.12% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $12.52 | +27.80% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $25.75 | +74.76% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $7.47 | +368.54% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $11.63 | +252.54% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $164.84 | +5.56% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $24.92 | +104.65% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $22.09 | -63.78% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $98.05 | -9.23% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $7.78 | -61.44% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $29.71 | -46.15% | 9 | Apr 2, 2020 |
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $175.58
Upside: +17.33%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $57.33
Upside: +27.33%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $47.44
Upside: +45.45%
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $5.61
Upside: +185.20%
Regeneron Pharmaceuticals
Sep 24, 2024
Downgrades: Market Perform
Price Target: $1,175 → $1,077
Current: $701.85
Upside: +53.45%
Oruka Therapeutics
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $20.31
Upside: +116.64%
Vaxcyte
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $86.53
Upside: +76.82%
Theravance Biopharma
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $9.59
Upside: +4.28%
HilleVax
Jul 9, 2024
Downgrades: Market Perform
Price Target: $28 → $2
Current: $1.86
Upside: +7.53%
AnaptysBio
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $14.55
Upside: +223.02%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $263.38
Upside: +20.74%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $17.16
Upside: -35.90%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $767.76
Upside: -40.35%
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $46.96
Upside: -10.56%
Feb 8, 2023
Maintains: Outperform
Price Target: $374 → $365
Current: $397.27
Upside: -8.12%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $92.57
Upside: -1.70%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $26.36
Upside: +82.09%
Jan 20, 2023
Maintains: Outperform
Price Target: $194 → $186
Current: $144.47
Upside: +28.75%
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $11.57
Upside: -13.57%
Jun 24, 2022
Maintains: Market Perform
Price Target: $7 → $10
Current: $15.52
Upside: -35.57%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $14.58
Upside: +153.77%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $122.97
Upside: +43.12%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $12.52
Upside: +27.80%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $25.75
Upside: +74.76%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $7.47
Upside: +368.54%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $11.63
Upside: +252.54%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $164.84
Upside: +5.56%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $24.92
Upside: +104.65%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $22.09
Upside: -63.78%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $98.05
Upside: -9.23%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $7.78
Upside: -61.44%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $29.71
Upside: -46.15%